Related Experiment Video
Updated: Dec 27, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
585
Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with
Takaaki Oba1, Kazuma Maeno2, Daiya Takekoshi1
1Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, Japan.
BMC Cancer
|February 29, 2020
Summary
A significant drop in the prognostic nutritional index (PNI) during neoadjuvant chemotherapy (NAC) indicates a poorer prognosis for breast cancer patients. Maintaining nutritional status during NAC may improve treatment outcomes.
Area of Science:
- Oncology
- Clinical Nutrition
- Biostatistics
Background:
- The prognostic nutritional index (PNI) is a key indicator of patient outcomes in various cancers.
- Its role in breast cancer patients undergoing neoadjuvant chemotherapy (NAC) requires further investigation.
Purpose of the Study:
- To evaluate the prognostic significance of PNI changes in breast cancer patients receiving NAC.
Main Methods:
- Retrospective analysis of 191 breast cancer patients who underwent NAC and surgery (2005-2016).
- PNI calculated using serum albumin and total lymphocyte count.
- Analysis of PNI changes (ΔPNI) and their correlation with disease-free survival (DFS).
Main Results:
- PNI significantly decreased in 94.7% of patients post-NAC (p < 0.01).
- A high ΔPNI (≥5.26) was associated with significantly poorer DFS (p = 0.015).
- High ΔPNI emerged as an independent risk factor for DFS (p = 0.042).
Conclusions:
- A substantial decrease in PNI during NAC is a predictor of poor prognosis in breast cancer.
- Strategies to maintain nutritional status during NAC may enhance treatment outcomes.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
474
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
474
01:21Cancer Survival Analysis
594
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
594
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
565
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
565
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
534
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
534
02:59Cancer Prevention
7.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.5K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
734
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
734